Preclinical research has shown that CAR T cells directed against the urokinase plasminogen activator receptor can attack both ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

BRCA1-Associated Protein 1 and Enhancer of Zeste Homolog 2: Pathway Interaction and Therapeutic Intervention in Breast Cancer, Mesothelioma, and Lymphoma The introduction of T-cell–based therapeutics ...

This article and associated images are based on a poster originally authored by Alex Chenchik, Lester Kobzik, Tianbing Liu, Dongfang Hu, Kitt Paraiso, Khadija Ghias, and Paul Diehl and presented at ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

CD19 chimeric antigen receptor (CAR) T-cell therapy showed potential in treating patients with refractory systemic lupus erythematosus (SLE), with B-cell depletion and disease activity reduction ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...